Saline Heart Group Pa

CLIA Laboratory Citation Details

3
Total Citations
9
Total Deficiencyies
6
Unique D-Tags
CMS Certification Number 04D1026830
Address 1000 Hwy 35 North, Suite 8, Benton, AR, 72019
City Benton
State AR
Zip Code72019
Phone(501) 315-4008

Citation History (3 surveys)

Survey - August 13, 2024

Survey Type: Standard

Survey Event ID: 1LA911

Deficiency Tags: D5415 D5469 D5441 D5783

Summary:

Summary Statement of Deficiencies D5415 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(c) Reagents, solutions, culture media, control materials, calibration materials, and other supplies, as appropriate, must be labeled to indicate the following: (1) Identity and when significant, titer, strength or concentration. (2) Storage requirements. (3) Preparation and expiration dates. (4) Other pertinent information required for proper use. This STANDARD is not met as evidenced by: Observation and interview determined that the laboratory failed to label two of two bottles of wash solution with identity, storage requirements, and preparation and expiration dates. Findings follow: A) During a tour of the laboratory on 8/13/24 at 02: 17 p.m. two plastic white colored bottles were observed partially filled with clear liquid. One bottle was labeled "Alfa Wassermann System Diluent lot 605522 expiration 2024-08-31" the second was labeled "Alfa Wassermann System Diluent lot 481716 expiration 2023-12-31". Both bottles were uncapped. B) During an interview on 8/13/24 at 02:17 p.m., testing personnel identified as number 4 on the CMS 209 form, when asked what the bottle contained, said one bottle contained water and the second contained alcohol and they were used to rinse intrument probe and verified that the bottles were mislabeled as to contents, storage requirements, and preparation and expiration dates. D5441 CONTROL PROCEDURES CFR(s): 493.1256(a)(b)(c)(g) (a) For each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process. (b) The laboratory must establish the number, type, and frequency of testing control materials using, if applicable, the performance specifications verified or established by the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- laboratory as specified in 493.1253(b)(3). (c) The control procedures must-- (c)(1) Detect immediate errors that occur due to test system failure, adverse environmental conditions, and operator performance. (c)(2) Monitor over time the accuracy and precision of test performance that may be influenced by changes in test system performance and environmental conditions, and variance in operator performance. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Review of the laboratory policy and procedure "Quality Control (QC) of Patient Test Systems", Levey-Jennings (LJ) Report September 2023 for Serum Glutamic Pyruvate Transaminase (ALT), and Aspartate Transaminase (AST) analysis, and through interviews with laboratory staff, determined the laboratory failed to monitor, over time, the accuracy of chemistry test results for those analytes. Survey findings include: A) A review of the general policy and procedure manual revealed a quality control policy stating " Review previous data points on LJ plots for scatter, shifts, or trends. A shift is defined as the following: when five data points in a row have fallen on one side of the mean. Remedial action is to be taken if this situation is found, to include: changing reagent packs; re-calibration of assays; adjustment of means if instructed by technical support or the lab consultant." B) A review of the September 2023 LJ report for Alfa Wassermann Chemistry Controls Level 1 and Level 2 lot numbers 1501 UNCM and 1166 UECM respectively for ALT and AST analysis revealed that QC results for ALT analysis were recorded as below the mean for 16 of 16 times for both levels and QC results for AST analysis were recorded as below the mean for 12 of 13 times for level 1 and 15 of 15 times for level 2. C) A review of the technical consultant quality assurance reports for 2023 found no mention of shifts in ALT or AST analysis. D) Upon request, the laboratory was unable to provide documentation of

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 9, 2023

Survey Type: Standard

Survey Event ID: DIEC11

Deficiency Tags: D5415 D5469 D5441

Summary:

Summary Statement of Deficiencies D5415 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(c) Reagents, solutions, culture media, control materials, calibration materials, and other supplies, as appropriate, must be labeled to indicate the following: (1) Identity and when significant, titer, strength or concentration. (2) Storage requirements. (3) Preparation and expiration dates. (4) Other pertinent information required for proper use. This STANDARD is not met as evidenced by: Through review of package inserts, observation, and interview it was determined that the laboratory did not change expiration dates on control materials after opening as required by manufacturer. Finding follow: A) Review of the package insert for Liquichek Hematology Controls (A) revealed that the product expires in twenty-one days after vial is opened and the expiration dates should be changed as required after opening. B) On 1/9/2023 at 1:00pm the surveyor observed, Liquichek Hematology Controls (A) in use , that did not have new expiration dates indicated on the testing materials. C) In an interview on 1/09/2023 at 1:10pm laboratory staff member (number 4 on form CMS 209) confirmed that no dates were written on the vials when the controls were put into use and, when asked when the control material was put into use, stated that she did not know. D5441 CONTROL PROCEDURES CFR(s): 493.1256(a)(b)(c)(g) (a) For each test system, the laboratory is responsible for having control procedures that monitor the accuracy and precision of the complete analytic process. (b) The laboratory must establish the number, type, and frequency of testing control materials using, if applicable, the performance specifications verified or established by the laboratory as specified in 493.1253(b)(3). (c) The control procedures must-- (c)(1) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- Detect immediate errors that occur due to test system failure, adverse environmental conditions, and operator performance. (c)(2) Monitor over time the accuracy and precision of test performance that may be influenced by changes in test system performance and environmental conditions, and variance in operator performance. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Through a review of the Individualized Quality Control Plans (IQCP) for the D-Dimer assay performed on the PathFast immuno analyzer, and through interviews with laboratory staff, it was determined the laboratory failed to establish the number and type of control materials used for D-Dimer assays. Survey findings follow: A) Through review of the IQCP for D-Dimer assays performed on the PathFast immunoanalyzer it was determined the Quality Control Plan failed to state the number and frequency of controls to be run or the specific type of control which would be used in the D-Dimer assay. B) In an interview at 12:20 p.m. on 1/9/2023, laboratory employee #2 (as listed on the form CMS-209) confirmed the lack of specific type of control in the Quality Control Plan for D-Dimer assay. D5469 CONTROL PROCEDURES CFR(s): 493.1256(d)(10)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- Establish or verify the criteria for acceptability of all control materials. (i) When control materials providing quantitative results are used, statistical parameters (for example, mean and standard deviation) for each batch and lot number of control materials must be defined and available. (ii) The laboratory may use the stated value of a commercially assayed control material provided the stated value is for the methodology and instrumentation employed by the laboratory and is verified by the laboratory. (iii) Statistical parameters for unassayed control materials must be established over time by the laboratory through concurrent testing of control materials having previously determined statistical parameters. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Through review of quality control records, control manufacturer ' s product inserts, and interview, it was determined that the laboratory did not follow established statistical parameters (standard deviation) in establishing acceptable range for complete blood cell (CBC) analysis control materials in one of three months reviewed. Findings follow: A) In an interview conducted on 1/9/23 at 09:15 a.m. , the laboratory staff member (# 2 on the CMS 209 form) stated that acceptable ranges for three levels of Cell-Dyne 18 Plus Control material used for quality control for all parameters of CBC analysis were established by using "historical standard deviations (SD)" determined by the laboratory and provided a list of those SD's to the surveyor. B) Review of the manufacturer's package insert for Cell-Dyne 18 Plus Control revealed " the recovery ranges are intended to reflect inter-laboratory and inter- instrument variability; thus, they are wider than the +/- 2 SD range for one instrument". C) Review of quality control results for September 2022 for Cell-Dyne 18 Plus Control, lot numbers L2234, N2234 and H2234 used by the laboratory -- 2 of 3 -- revealed that acceptable ranges in use for all parameters of CBC analysis matched those provided by the manufacturer and not the historical SD's on the list provided by the laboratory. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - June 21, 2018

Survey Type: Standard

Survey Event ID: RV7D11

Deficiency Tags: D5791 D5481

Summary:

Summary Statement of Deficiencies D5481 CONTROL PROCEDURES CFR(s): 493.1256(f)(g) (f) Results of control materials must meet the laboratory's and, as applicable, the manufacturer's test system criteria for acceptability before reporting patient test results. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: . Through a review of chemistry quality control results for January, March and April 2018, patient medical records, technical consultant report for March 2018, as well as interviews with staff, it was determined that patients were reported when results of control material failed to meet the laboratory's criteria for acceptability. As evidenced by: A. A review of the ACE Alera Chemistry analyzer daily quality control printouts for 3/7/2018 revealed the Calcium result on the Level 1 Chemistry Control (Lot #1213UNCM) was outside of the acceptable criteria. The control was tested four times with all four results being unacceptable. The acceptable range listed for Calcium is 10.0 to 11.2. Results documented for 3/7/2018 are 0.4, 9.6, 9.5, and 9.4. B. A review of the technical consultant report for March 2018 revealed the laboratory did not have documentation of acceptable quality control result for Level I Calcium (Lot #1213UNCM). C. Through a review of patient chemistry reports it was determined four patients had Calcium results reported on 3/7/2018, when the chemistry control was unacceptable: Patient #3276, patient #7904, patient #15850 and patient #9346. D. In an interview on 06/21/2018 at 1423, technical consultant ( as listed on form confirmed there were no acceptable quality control results for Calcium on 3/7/2018, and that patient results were reported. D5791 ANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1289(a)(c) (a) The laboratory must establish and follow written policies and procedures for an Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the analytic systems specified in 493.1251 through 493.1283. (c) The laboratory must document all analytic systems assessment activities. This STANDARD is not met as evidenced by: . Through a review of the laboratory policy and procedure manual, review of the instrument validation documentation for the Pathtest Chemistry analyzer, technical consultant reports, lack of documentation, as well as interviews with staff, it was determined the laboratory failed to follow written policies and procedures to assess and correct problems in the analytic systems. As evidenced by: A. The Quality Assurance (QA) Plan in the procedure manual states: "This laboratory has established the following goals for our QA program. We intend to identify problems in our laboratory and apply

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access